{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:30:56Z","timestamp":1792369856772,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ophtha.2014.04.044","type":"journal-article","created":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T11:03:03Z","timestamp":1403262183000},"page":"1885-1891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Rituximab Therapy for Refractory Scleritis"],"prefix":"10.1016","volume":"121","clinical-trial-number":[{"clinical-trial-number":"nct00415506","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eric B.","family":"Suhler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndell L.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Beardsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy R.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirichai","family":"Pasadhika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"de Saint Sardos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2014.04.044_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/ncprheum0454","article-title":"Therapy insight: scleritis and its relationship to systemic autoimmune disease","volume":"3","author":"Smith","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.ophtha.2014.04.044_bib2","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0161-6420(94)31178-X","article-title":"Scleritis associated with rheumatoid arthritis and with other systemic immune-mediated diseases","volume":"101","author":"Sainz de la Maza","year":"1994","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.04.044_bib3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ophtha.2003.06.006","article-title":"Evaluation of patients with scleritis for systemic disease","volume":"111","author":"Akpek","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.04.044_bib4","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ajo.2009.07.021","article-title":"Scleritis and systemic disease association in a community-based referral practice","volume":"148","author":"Raiji","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.04.044_bib5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1517\/14656566.2013.772982","article-title":"Pharmacotherapy of scleritis: current paradigms and future directions","volume":"14","author":"Beardsley","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ophtha.2014.04.044_bib6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0002-9394(00)00710-8","article-title":"Episcleritis and scleritis: clinical features and treatment results","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.04.044_bib7","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2014.04.044_bib8","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00277-012-1534-y","article-title":"Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting","volume":"91","author":"Witzens-Harig","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ophtha.2014.04.044_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1634\/theoncologist.2010-0306","article-title":"U.S. Food and Drug Administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia","volume":"16","author":"Casak","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.ophtha.2014.04.044_bib10","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1177\/0961203312446627","article-title":"Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study","volume":"21","author":"Fern\u00e1ndez-Nebro","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.ophtha.2014.04.044_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2014.04.044_bib12","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archopht.1987.01060060079037","article-title":"Intravenous pulse methylprednisolone in scleritis","volume":"105","author":"McCluskey","year":"1987","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.04.044_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1442-9071.1991.tb00663.x","article-title":"Prediction of response to treatment in patients with scleritis using a standardised scoring system","volume":"19","author":"McCluskey","year":"1991","journal-title":"Aust N Z J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.04.044_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2013.8179","article-title":"Rituximab Therapy for refractory orbital inflammation: results of a phase 1\/2, dose-ranging, randomized clinical trial","author":"Suhler","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.04.044_bib15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/archophthalmol.2009.141","article-title":"Infliximab therapy for refractory uveitis: 2-year results of a prospective trial","volume":"127","author":"Suhler","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.04.044_bib16","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3129\/i09-061","article-title":"Infliximab for the treatment of active scleritis","volume":"44","author":"Sen","year":"2009","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.04.044_bib17","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.04.044_bib18","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2014.04.044_bib19","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study)","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ophtha.2014.04.044_bib20","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24454","article-title":"Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis","volume":"60","author":"Taylor","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2014.04.044_bib21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.autrev.2011.07.001","article-title":"Anti-CD 20 monoclonal antibody (Rituximab) treatment for inflammatory ocular diseases","volume":"11","author":"Miserocchi","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ophtha.2014.04.044_bib22","first-page":"20","article-title":"Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab\u2013results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial","volume":"35","author":"Mease","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.ophtha.2014.04.044_bib23","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ophtha.2010.08.027","article-title":"A\u00a0standardized grading system for scleritis","volume":"118","author":"Sen","year":"2011","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642014003984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642014003984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:05:31Z","timestamp":1758981931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642014003984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0161642014003984"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.044","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab Therapy for Refractory Scleritis","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}